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Double-stranded RNA mediates interferon regulatory factor 3
activation and interleukin-6 production by engaging Toll-like
receptor 3 in human brain astrocytes
Introduction
Toll-like receptors (TLR) play a key role in the innate
immune response by recognizing pathogens. They regu-
late the production of inflammatory mediators and
cytokines.1 Eleven members of the TLR family have
been identified, each recognizing unique molecular pat-
terns associated with different classes of pathogens.1,2
TLR3 mediates signalling in response to double-
stranded RNA (dsRNA),3 suggesting that TLR3 may
recognize viral infections. The other TLRs mainly
appear to be responsible for recognizing bacterial
ligands.
Recently, TLR expression and function have been
reported in the central nervous system (CNS). Human
astrocytes and oligodendrocytes express TLR2 and TLR3,
whereas microglia express various TLRs.4,5 TLR4 is exclu-
sively localized in microglia and mediates lipopoly-
saccharide (LPS)-induced oligodendrocyte injury.6 Innate
immunity, especially TLR-mediated immune responses on
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Summary
Toll-like receptor 3 (TLR3) participates in the innate immune response by
recognizing viral pathogens. In this study, human brain astrocytes were
found to constitutively express TLR3, and this expression was increased
by interferon-c (IFN-c) or double-stranded RNA (dsRNA). Treatment
employing dsRNA in astrocytes induced IFN regulatory factor 3 (IRF3)
phosphorylation, dimer formation and nuclear translocation followed by
STAT1 activation. This treatment also activated nuclear factor-jB, p38
and c-Jun N-terminal kinase significantly, while activating extracellular
signal-regulated kinase to a lesser extent. Treatment with anti-TLR3 anti-
body inhibited dsRNA-mediated interleukin-6 (IL-6) production. In the
presence of mitogen-activated protein kinase inhibitors, astrocytes failed
to secrete IL-6 in response to dsRNA treatment. Therefore, dsRNA-
induced IL-6 production is dependent on mitogen-activated protein
kinases and type I IFN production is dependent on IRF3 in brain astro-
cytes. These results suggest that brain inflammation, which produces
inflammatory cytokines and type I IFNs, may enhance TLR3 expression
in astrocytes. Additionally, upregulated TLR3 might modulate inflamma-
tory processes by producing proinflammatory cytokines.
Keywords: astrocytes; cytokine; interferon-regulatory factor 3; mitogen-
activated protein kinase; Toll-like receptor 3
Abbreviations: CNS, central nervous system; dsRNA, double-stranded RNA; DMEM, Dulbecco’s modified Eagle’s minimum
essential medium; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic
mobility shift assay; ERK, extracellular signal-regulated kinase; FCS, fetal calf serum; IFN, interferon; IgG, immunoglobulin G;
IL-6, interleukin-6; IRF3, interferon regulatory factor 3; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAL, MyD88-
adaptor-like; MAPK, mitogen-activated protein kinase; NF-jB, nuclear factor-jB; PBS, phosphate-buffered saline; PBST,
PBS–Tween-20; RT-PCR, reverse transcription–polymerase chain reaction; SDS–PAGE, sodium dodecyl sulphate–polyacrylamide
gel electrophoresis; STAT1, signal transducer and activator of transcription 1; TICAM-1, Toll/interleukin-1 receptor-containing
adaptor molecule-1; TIRAP, Toll/interleukin-1 receptor domain-containing adaptor protein; TLR, Toll-like receptor; TRIF,
Toll/interleukin-1 receptor domain-containing adaptor-inducing interferon-b.
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glial cells, has been related both to protection against
bacterial infections (Staphylococcus aureus)7 and CNS
immunopathology.8
Astrocytes play a significant role during infectious and
autoimmune CNS diseases. Astrocytes have privileged and
strategic locations at the blood–brain barrier and within
CNS tissue, so could be ideal sentinel cells, capable of
sensing viral pathogens. This would induce a ‘state of
alert’ in the CNS before viruses infect their target cells.
Despite the importance of viral inflammation and innate
immunity in neuropathies,9 molecular responses to
dsRNA in the brain are poorly understood. Human cellu-
lar RNA was reported to be a potential TLR3 ligand,10
and it is well known that RNA is a constituent of the pla-
ques found in patients with Alzheimer disease.11,12 There-
fore, RNA released from necrotic cells could come in
contact with microglia or astrocytes. Although studies
report that TLR3 is expressed preferentially in astro-
cytes,5,13 the function of TLR3 in the brain is not com-
pletely understood. We investigated the role of TLR3 in
human brain astrocytes. Primary human astrocytes were
isolated, and TLR3 expression and activation in response
to dsRNA and other signalling molecules were examined
in these cells. Our results indicate that astrocytes have a
distinct TLR3 cytoplasmic expression pattern and directly
respond to dsRNA, leading to activation of interferon reg-
ulatory factor 3 (IRF3), mitogen-activated protein kinase
(MAPK) and nuclear factor-jB (NF-jB) and to inter-
leukin-6 (IL-6) secretion.
Materials and methods
Primary astrocyte preparation and maintenance
Five different astrocyte cultures were prepared from five
20- to 25-week-old human fetuses obtained from therapeu-
tic abortions after obtaining the permission of the institu-
tional review board (IRB) (IRB No. CR07014). Astrocytes
were purified as previously described with slight modifica-
tions.14 The tissue was dissected using a syringe and was
digested with trypsin–ethylenediaminetetraacetic acid
(EDTA). The cells were cultured in 10% fetal calf serum
(FCS; Gibco BRL, Grand Island, NY)–Dulbecco’s modified
Eagle’s minimum essential medium (DMEM; Gibco BRL)
containing 1% non-essential amino acids (Sigma, St Louis,
MO), penicillin and streptomycin (Gibco BRL) at 37 in
5% CO2. After 2 weeks in culture, cells were shaken
(200 r.p.m. for 2 hr) on a shaker (Vision Scientific Co.,
Bucheon, Korea) once a week for 2 weeks and the non-
adherent cells were removed. Astrocyte cultures were rou-
tinely > 98% positive for glial fibrillary acidic protein, and
< 1% of the cells were microglia based on human leucocyte
antigen DR positive staining. Cell subcultures started at
2 · 104 cells/ml in a 75-cm2 tissue culture flask. The med-
ium was changed on the third day and then twice a week.
An astrocyte monolayer was usually observed on the 10th
day. The astrocytes were maintained for up to 8 weeks after
purification.
Reagents
The following reagents were used at the indicated concen-
trations and times: polyriboinosinic polyribocytidylic acid
[poly(I:C); Amersham Pharmacia Biotech, Milwaukee,
WI], polyribocytidylic acid [poly(C); Amersham], polyde-
oxyriboinosinic polydeoxyribocytidylic acid [poly(dI:dC);
Amersham], interferon-c (IFN-c; Genzyme, Cambridge,
MA), LPS (Escherichia coli 026:B6; Sigma), U0126 (Cal-
biochem, La Jolla, CA), SB203580 (Calbiochem), c-Jun
N-terminal kinase (JNK) inhibitor II (Calbiochem).
Reverse transcription–polymerase chain reaction
(RT-PCR)
Total RNA was isolated using an RNeasy kit (Qiagen, Santa
Claris, CA). Total RNA (2 lg) was used to synthesize
complementary DNA with 01 optical density (O.D.) ran-
dom hexamer (Pharmacia, Uppsala, Sweden) and 200 U
Moloney-murine leukaemia virus reverse transcriptase
(Gibco BRL). The TLR3 primers used were: forward, 50-
GATCTGTCTCATAATGGCTTG-30; reverse, 50-GACAGA-
TTCCGAATGCTTGTG-30. Conditions for the PCR were as
follows: denaturing at 94 for 30 seconds, annealing at 52
for 30 seconds and extension at 72 for 1 min. The PCR
buffer contained 10 mM Tris–HCl (pH 10), 20 mM MgCl2,
50 mM KCl and 125 U Taq polymerase (Takara, Tokyo,
Japan). After 28 cycles, an additional 10 min extension
at 72 was added. b-Actin was used as an internal control
and the RT-PCR assays were performed three times and
representative results are shown.
Flow cytometry
Astrocytes (5 · 106) were incubated with goat anti-human
TLR3 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) for 30 min at 4 in phosphate-buffered saline (PBS)
with 1% bovine serum albumin. After the cells were washed
twice, fluorescein isothiocyanate-labelled rabbit anti-goat
immunoglobulin G (IgG; Jackson ImmunoResearch, Balti-
more, MD) was added and incubated for 30 min at 4. For
intracellular staining, cells were fixed with 4% paraformal-
dehyde for 20 min at room temperature and permeabilized
with 1% bovine serum albumin-PBS containing 01%
Triton X-100 for 5 min at room temperature. After wash-
ing, the cells were incubated with anti-TLR3 antibody for
30 min at 4. Cells were then washed twice and incubated
with fluorescein isothiocyanate-labelled secondary antibody
at 4 for 30 min. Cell fluorescence was determined using
FACSCaliber (BD Biosciences, San Diego, CA) and
analysed using CELLQUEST 3.3 (BD Biosciences).
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Electrophoretic mobility shift assay (EMSA)
The EMSA was performed using 6 lg of nuclear extract.
Double-stranded NF-jB synthetic oligonucleotides (50-
AGTTGAGGGGACTTTCCCAGGC-30) were purchased
from Promega (Madison, WI) and end-labelled with
[c-32P]ATP (Amersham) and T4 polynucleotide kinase
(NEB, Beverly, MA). The nuclear extract was incubated
with 00175 pmol (>104 counts/min) radiolabelled NF-jB
probe and 1 lg poly(dI:dC)–poly(dI:dC) (Amersham) for
30 min in binding buffer [10 mM Tris–HCl (pH 76),
20 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glyc-
erol]. Binding reactions were performed on ice in a 20 ll
total volume. Samples were loaded on a non-denaturing
6% polyacrylamide gel and electrophoresis was performed
for 3 hr at 150 V. The gel was dried and exposed to high-
performance autoradiography film. One-hundred-fold
excesses of unlabelled NF-jB probe and mutant NF-jB
probe (Santa Cruz Biotechnology) were used as specific
competitors, and an unrelated oligonucleotide AP-1 probe
was used as a non-specific competitor. The supershift
assays were performed by preincubating nuclear extracts
with 2 lg polyclonal p65 or p50 antibodies (Santa Cruz
Biotechnology) on ice for 30 min in the aforementioned
reaction conditions.
Enzyme-linked immunosorbent assay (ELISA)
Astrocytes were cultured in a 96-well plate, with 2 · 104
cells per well. The culture medium was collected to mea-
sure IL-6 production. The IL-6 in the supernatant was
quantified using commercial ELISA kits (BD Biosciences)
according to the manufacturer’s instructions. The experi-
ments were performed in triplicate. The anti-TLR3 anti-
body was purchased from R&D Systems (Minneapolis,
MN).
Western blotting
Cells were lysed by sonicating three times for 10 seconds.
Lysates were centrifuged for 10 min at 10 000 g, and the
soluble supernatant was used for Western blot analysis.
The total protein was resolved on 10% or 12% sodium
dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred to nitrocellulose membrane.
The blots were blocked in PBS with 01% Tween-20
(PBST) containing 5% non-fat milk, and were incubated
with the appropriate primary antibody at a 1 : 1000 dilu-
tion. After three washes in PBST, the blots were incubated
in peroxidase-conjugated secondary antibody at 1 : 5000.
They were then washed three times in PBST and devel-
oped with an ECL system (Amersham). The polyclonal
anti-TLR3 antibody was purchased from IMGENEX (San
Diego, CA) (IMG-315A). Anti-extracellular signal-regu-
lated kinase (ERK), anti-phospho-ERK, anti-p38 MAPK,
anti-phospho-p38 MAPK, anti-JNK, anti-phospho-JNK,
anti-phospho-signal transducer and activator of transcrip-
tion 1 (STAT1), anti-STAT1, anti-phospho-IjBa and
anti-IjBa were all purchased from Cell Signaling Tech-
nology (Beverly, MA). Goat anti-mouse IgG (BD Bio-
sciences), goat anti-rabbit IgG (Jackson ImmunoResearch)
and rabbit anti-goat IgG (Jackson ImmunoResearch)
secondary antibodies were used.
Native PAGE
Astrocytes were collected and lysed in native lysis buffer
[50 mM Tris–HCL, pH 75, 150 mM NaCl, 1 mM EDTA,
pH 80, 1 mM Na3VO4, 1 mM b-glycerophosphate, 1 mM
phenylmethylsulphonyl fluoride in ethanol, protease
inhibitor cocktail and 1% Nonidet P-40]. An SDS-free
75% polyacrylamide gel was prerun with 25 mM Tris–
HCl and 192 mM glycine with 1% deoxycholate in the
cathode chamber only for 30 min at 40 mA. Samples
(10 lg) were combined 1 : 1 with native sample
buffer (Biorad, Hercules, CA), loaded and electrophoresed
for 60 min at 35 mA. Proteins were transferred to mem-
branes and probed for IRF3 dimerization with rabbit
anti-IRF3 (Novus Biologicals, Inc., Littleton, CO).
Immunofluorescence staining and analysis by confocal
microscopy
Astrocytes were grown in eight-well Nunc Lab-Tec II
chambered coverglasses (Nalge Nunc, Naperville, IL) with
10% FCS–DMEM (Gibco BRL) containing 1% non-essen-
tial amino acids (Sigma), penicillin and streptomycin
(Gibco BRL) at 37 in 5% CO2. Cells were fixed, permea-
bilized and stained with rabbit anti-IRF3 polyclonal anti-
body (Novus Biologicals, Inc.) for 45 min at room
temperature. Cells were washed three times and further
incubated with 25 lg/ml Alexa Fluor-conjugated second-
ary antibodies (Alexa-594, Molecular Probes, Carlsbad,
CA) for 1 hr at room temperature and analysed by confo-
cal microscopy. The confocal microscopy studies were
performed with a Zeiss Axiovert 100-M inverted micro-
scope equipped with an LSM 510 (Carl Zeiss, Jena,
Germany) laser scanning unit and a 14 NA · 63 Plan-
Apochromat oil-immersion objective.
Luciferase reporter gene assay
Luciferase reporter gene assay was performed with the
pIL6-jB-Luc (NF-jB promoter) plasmid. Fetal astrocytes
were grown in 12-well plates with 10% FCS–DMEM
(Gibco BRL) containing 1% non-essential amino acids
(Sigma), penicillin and streptomycin (Gibco BRL) at 37
in 5% CO2. Cells were cotransfected with 005 lg/ml of
pIL6-jB-Luc plasmid and pCMV-b-galactosidase vector
(Promega). After 24 hr, cells were stimulated with
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poly(I:C) for 6 hr, and thereafter, cell extracts were pre-
pared. The luciferase activity was measured by a Lucifer-
ase Reporter Assay System (Promega). b-Galactosidase
activity was measured with O-nitrophenyl-b-D-galactopyr-
anoside as substrate. The luciferase activity reported in
the figures is normalized for transfection efficiency with
the b-galactosidase activity.
Statistical analysis
Data were statistically evaluated by one-way analysis of
variance (ANOVA) followed by the Fisher’s protected least
significant difference test for multiple comparisons. A
P-value < 005 was considered to be statistically significant.
Results
TLR3 expression in astrocytes and upregulation in
response to poly(I:C) or IFN-c
To evaluate TLR3 expression in astrocytes, RT-PCR, Wes-
tern blotting and flow cytometric analysis were per-
formed. TLR3 messenger RNA was detected in cultured
astrocytes and upregulated by inflammatory stimulation,
such as dsRNA, LPS or IFN-c treatment (Fig. 1a). In
response to IFN-c, TLR3 protein levels increased signifi-
cantly (Fig. 1b). Flow cytometric analysis revealed that
TLR3 was localized more in the cytoplasm than on the
cell surface but after stimulation with dsRNA, the cell
surface localization of TLR3 increased (Fig. 1c). These
results show constitutive TLR3 expression in astrocytes,
which increased robustly with inflammatory stimuli.
NF-jB activation following poly(I:C) treatment in
brain astrocytes
To examine whether dsRNA activates NF-jB in astrocytes
EMSA was performed. Poly(I:C) efficiently acti-
vated NF-jB (Fig. 2a) in a manner similar to the
positive control (LPS stimulation). In contrast, poly(C) or
poly(dI:dC) did not activate NF-jB efficiently (Fig. 2a).
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Figure 1. Expression and upregulation of Toll-like receptor 3
(TLR3) in astrocytes. (a) Cells were treated with 25 lg/ml poly(I:C),
100 ng/ml lipopolysaccharide (LPS), 1000 U/ml interferon-c (IFN-c)
for 5 hr or left untreated. Semiquantitative reverse transcription–
polymerase chain reaction (RT-PCR) for TLR3 expression was per-
formed. b-Actin was used as an internal control. (b) Cells were incu-
bated with 1000 U/ml IFN-c for 24 hr, and Western blots were
performed. b-Tubulin was used as an internal control. (c) Cells were
stimulated with 25 lg/ml poly(I:C) for 24 hr. Results shown are
representative of three independent samples.
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Figure 2. Nuclear factor-jB (NF-jB) activation with poly(I:C) stim-
ulation in astrocytes. (a) Cells were treated with 100 ng/ml lipopoly-
saccharide (LPS), 25 lg/ml poly(I:C), 25 lg/ml poly(C) or 25 lg/ml
poly(dI:dC) for 1 hr or left untreated. The NF-jB activation was
analysed by electrophoretic mobility shift assay. (b) NF-jB activation
increased in a time-dependent manner. Cells were stimulated with
25 lg/ml poly(I:C) for the indicated times. (c) NF-jB activation
increased in a dose-dependent manner. Cells were treated with the
indicated doses of poly(I:C) for 1 hr. (d) Cells were incubated with
10 lg/ml poly(I:C). After stimulation, cells were lysed by sonication
and the lysates were analysed by Western blot using antibodies to
p-IjBa or IjBa. (e) Antibody supershift assays were performed by
preincubating poly(I:C)-treated nuclear extracts from astrocytes with
the indicated antibodies. A 100-fold excess of unlabelled oligonucleo-
tide (cold NF-jB), mutant oligonucleotide (mutant NF-jB) or non-
specific oligonucleotide (AP-1) was used for competition assays. The
data are representative of results obtained from three different exper-
iments. (f) Luciferase reporter gene assay was performed. Fetal astro-
cytes were cotransfected with 005 lg/ml of pIL6-jB-Luc plasmid
and pCMV-b-galactosidase vector. After 24 hr, cells were stimulated
with poly(I:C). The luciferase activity was measured by a Luciferase
Reporter Assay System. Luciferase activity is normalized for transfec-
tion efficiency with the b-galactosidase activity. *P < 005, signifi-
cantly different from controls at the same treated time.
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The activation of NF-jB occurred 30 min after poly(I:C)
treatment and reached a maximum level at 180 min
(Fig. 2b). The activation of NF-jB increased with
increased poly(I:C) concentration (Fig. 2c); treatment
with 100 lg/ml poly(I:C) induced significantly more NF-
jB activation than a 5 lg/ml poly(I:C) treatment. The
IjBa phosphorylation occurred efficiently after poly(I:C)
treatment (Fig. 2d). In a competition experiment, a 100-
fold excess of unlabelled NF-jB probe was incubated with
either a mutant NF-jB probe or an unrelated oligonu-
cleotide probe. A supershift assay using anti-p50 antibody
or anti-p65 antibody identified NF-jB components
(Fig. 2e). A luciferase reporter gene assay in primary
astrocytes also showed NF-jB activation induced by
poly(I:C) (Fig. 2f).
IL-6 production following poly(I:C) treatment in fetal
brain astrocytes
To investigate whether dsRNA induces IL-6 in astrocytes,
cells were incubated with poly(I:C) or poly(dI:dC) and
the culture supernatant was analysed using ELISA.
Poly(I:C) induced IL-6 release in a dose-dependent man-
ner (P < 0001) (Fig. 3a) but poly(dI:dC) did not induce
IL-6 production (Fig. 3a). To examine whether dsRNA-
induced IL-6 production in astrocytes is TLR3 dependent,
astrocytes were preincubated with anti-TLR3 antibody for
1 hr and cultured with poly(I:C) for 18 hr. Pretreating
astrocytes with the anti-TLR3 antibody suppressed
poly(I:C)-induced IL-6 release (Fig. 3b). This result indi-
cates that TLR3 expressed in astrocytes specifically recog-
nizes dsRNA and triggers downstream signals leading to
IL-6 production.
MAPK are involved in poly(I:C)-induced IL-6
production
To address whether dsRNA induces MAPK to stimulate
IL-6 production in astrocytes, cells were treated with
poly(I:C) and activation of ERK, p38 and JNK were
assessed by Western blotting. The dsRNA induced ERK,
p38 and JNK phosphorylation (Fig. 4); MAPK phosphor-
ylation was detected 30 min after poly(I:C) treatment and
increased until 90 min. At 90 min, p38 was phosphory-
lated fourfold (Fig. 4b) and JNK was phosphorylated two-
fold compared with controls (Fig. 4c). Phosphorylation of
ERK only increased slightly (13-fold) (Fig. 4a).
This result prompted the investigation of MAPK
involvement in dsRNA-induced IL-6 production. To con-
firm specific inhibition, cells were treated with MAPK
inhibitors at different concentrations. The astrocytes were
pretreated with MAPK inhibitors for 30 min and cultured
with poly(I:C) for 18 hr. Then the inhibition of IL-6 pro-
duction by MAPK inhibitors was measured by ELISA. The
MAPK inhibitors suppressed IL-6 production in a dose-
dependent manner. Treatment with U0126 (an ERK inhib-
itor) moderately decreased poly(I:C)-induced IL-6 pro-
duction (Fig. 4d) while treatment with either SB203580 (a
p38 inhibitor) or JNK inhibitor II (a JNK inhibitor) led to
a marked suppression of IL-6 production in poly(I:C)-
stimulated astrocytes. All the inhibitors reduced MAPK
activity in a dose-dependent manner (Fig. 4d).
IRF3, STAT1 and IjBa are activated by poly(I:C)
treatment
IRF3 phosphorylation, dimer formation and nuclear
translocation were assessed as measures of IRF3 activation
in response to dsRNA. The dsRNA induced IRF3 phos-
phorylation at 60 min, but this disappeared at 240 min
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Figure 3. Double-stranded RNA induces interleukin-6 (IL-6) pro-
duction in astrocytes through Toll-like receptor 3 (TLR3). (a) Cells
were cultured with poly(I:C) and poly(dI:dC) at the indicated con-
centrations for 24 hr. IL-6 in the supernatants was measured by
enzyme-linked immunosorbent assay (ELISA). Data are representa-
tive of results obtained from three separate experiments. (b) Cells
were pretreated with 10 lg/ml anti-TLR3 antibody for 1 hr. After
incubating with 2 or 20 lg/ml poly(I:C) for 18 hr, the medium was
collected and analysed by ELISA for IL-6 production. Pretreatment
with goat serum was similar to no antibody treatment. *P < 005,
significantly different from control or poly(dI:dC)-treated group (a)
and also significantly different from the group not treated with anti-
TLR3 antibody (b).
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after poly(I:C) treatment (Fig. 5a). Formation of IRF3
dimers was also detected at 60 min after poly(I:C) treat-
ment (Fig. 5a). Nuclear translocation of IRF3 was
observed at 1 hr after poly(I:C) treatment and persisted
until 2 hr after stimulation (Fig. 5b). The STAT1 activa-
tion began 240 min after poly(I:C) treatment (Fig. 6).
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Figure 4. Mitogen-activated protein kinase (MAPK) activation by double-stranded RNA in brain astrocytes. (a–c) Cells were incubated with
25 lg/ml poly(I:C) for the indicated times or left untreated. After the stimulation, cells were lysed by sonication and the lysates were analysed by
Western blot using antibodies to phosphorylated extracellular signal-regulated kinase (p-ERK), ERK, p-p38, p38, phosphorylated c-Jun N-termi-
nal kinase (p-JNK) and JNK. The fold induction was calculated as the ratio of phosphorylated MAPK to unphosphorylated MAPK. The data are
representative of three separate experiments (a–c). (d) Astrocytes were preincubated with the indicated concentrations of U0126 (ERK inhibitor),
SB203580 (p38 inhibitor), JNK inhibitor II (JNK inhibitor) or dimethyl sulphoxide (DMSO; control) for 30 min. After treatment, cells were cul-
tured with 100 lg/ml poly(I:C) for 18 hr. The supernatant was collected and analysed by enzyme-linked immunosorbent assay for interleukin-6
(IL-6) production. *P < 005, significantly different from poly(I:C) control at varying concentrations.
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Figure 5. Poly(I:C) induced interferon regula-
tory factor 3 (IRF3) activation in astrocytes.
(a) Cells were incubated with 10 lg/ml
poly(I:C). After stimulation, cell lysates were
separated by native polyacrylamide gel electro-
phoresis (PAGE). Both monomeric and
dimeric IRF3 were detected by rabbit anti-IRF3
antibody. (b) Cells were stimulated with
10 lg/ml poly(I:C) for the indicated time,
fixed, permeabilized and stained with rabbit
anti-IRF3 polyclonal antibody for 45 min at
room temperature. Then cells were washed
three times and incubated with 25 lg/ml
Alexa Fluor-conjugated secondary antibodies
(Alexa-594) for 1 hr at room temperature.
Cells were analysed by confocal microscopy at
· 40 magnification.
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Phosphorylation of IjBa occurred 30 min after poly(I:C)
treatment (Fig. 6), which suggests the activation of
NF-jB.
Discussion
In the present study, flow cytometry was performed to
assess the TLR3 expression pattern in cultured brain as-
trocytes. A previous study found TLR3 exclusively on the
surface of cultured astrocytes, and within intracellular
vesicles in cultured microglia.4 Here, we detected TLR3
protein through cell surface and intracellular staining,
both of which were upregulated by dsRNA stimulation.
Localization of TLR3 varies between different cell types:
TLR3 was detected on the cell surface in human fibro-
blasts,15 while it is intracellular in dendritic cells and reti-
nal pigment epithelial cells.16
Double-stranded RNA recognition by TLR3 has been
shown to be dependent on TLR3 localization. In this study,
we have shown that TLR3 is expressed on the cell surface
of astrocytes, although the expression is higher in the
cytoplasm. Recognition of dsRNA by extracellular TLR3 is
sufficient to induce cytokine production in brain astro-
cytes. In our study, astrocytes released IL-6 in response
to dsRNA treatment, but not in response to single-
stranded RNA or dsDNA. Adding an anti-TLR3 antibody
inhibited dsRNA-induced IL-6 secretion. Even in cells with
TLR3 localized in the endosomes, the inhibitory function
of anti-TLR3 antibodies is still controversial. Inhibiting
endosomal maturation, however, also inhibited dsRNA-
induced cytokine production in immature dendritic cells
with TLR3 localized to intracellular vesicles.17 Inhibition of
dsRNA-induced cytokine production with an anti-TLR3
antibody was shown in retinal pigment epithelial cells as
well.16
Recent studies have demonstrated that TLR3 sig-
nals through a MyD88-independent pathway, utilizing a
Toll/IL-1 receptor (TIR)-containing adaptor molecule
(TICAM-1)18 and a TIR domain-containing adaptor-
inducing IFN-b (TRIF)19 to NF-jB and IFN-b promoters.
In primary astrocytes, we assessed NF-jB activation after
dsRNA treatment. Activation of NF-jB was detected at
30 min and sustained for up to 180 min. It has been
suggested that MAPK are critical signalling molecules for
TLR-mediated cell activation.3 When HeLa cells were pre-
treated with ERK1/2 and p38 MAPK inhibitors, IL-6
production in response to dsRNA treatment was sup-
pressed.20 Cyclooxygenase-2 expression was found to be
dependent on MAPK activation21 and preincubation with
MAPK inhibitors decreased IL-6 production in a dose-
dependent manner. Therefore, MAPK phosphorylation
plays a central role in IL-6 production. Astrocytes
respond to TLR3 ligation by producing IL-6, CXCL-10
and IFN-b, implicating these cells as contributors to pro-
inflammatory responses.22,23 A recent paper showed that
TLR3 uses different signalling mechanisms. Inhibitors of
NF-jB, JNK and ERK reduce IL-8 and IFN-inducible
protein 10 (IP-10) expression in astrocytes, while phos-
phoinositide 3 kinase inhibition suppressed IP-10 expres-
sion, but upregulated IL-8 expression.24
Our data show that poly(I:C) induces IRF3 phosphory-
lation and dimer formation in brain astrocytes. The acti-
vated IRF3 was translocated to astrocyte nuclei 1 hr after
poly(I:C) treatment. Similar to other TLR3-expressing
cells,25 astrocytes efficiently produce type I IFNs in
response to dsRNA, or participate in provoking anti-viral
immunity. TLR3 enhanced the production of anti-inflam-
matory cytokines, including IL-9, IL-10 and IL-11, but not
of proinflammatory cytokines or type I IFNs, and it down-
regulated the p40 subunit of IL-12 and IL-23.26 This sug-
gests an immunomodulatory function of TLR3 signalling.
The protective role played by TLR3 against viruses in
astrocytes is still controversial. Transcription factors and
chemokine genes are activated through the TLR3 path-
way, but TLR3-mediated activation did not affect the level
of replication of Theiler’s murine encephalomyelitis
virus.27,28 The fact that poly(I:C) induced viperin/cig5 to
inhibit human immunodeficiency virus replication in
astrocytes also suggests a protective role.29 Two other
papers show that microglia recognize dsRNA through
TLR3 in mice,30 and that human neurons express TLR3
as intrinsic machinery to trigger antiviral responses.31
In addition to protecting against infection, other
immunological roles of TLR3 in the brain remain to be
described. There may be endogenous ligands for TLRs, so
it would be interesting to clarify the function of TLR3
and its molecular mechanisms in the brain. Some host-
derived TLR ligands have been identified. These include
heat-shock proteins32 and extracellular matrix breakdown
products.33,34 These molecules can activate TLRs, modu-
lating the immune response. Despite the ubiquitous
RNAse distribution, pathophysiological conditions might
poly(I:C) (10 μg/ml)
0 min 30 min 1 hr 2 hr 4 hr 
p-STAT1 (Tyr701)
STAT1
p-IκBα (Ser32)
IκBα
Figure 6. Poly(I:C) induced signal transducer and activator of tran-
scription 1 (STAT1) and nuclear factor-jB (NF-jB) activation in
astrocytes. Cells were stimulated with 10 lg/ml poly(I:C) for the
indicated time. Western blotting was performed with anti-phospho-
STAT1, anti-STAT1, anti-phospho-IjBa or anti-IjBa antibodies.
Goat anti-rabbit immunoglobulin G was used as secondary antibody.
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be associated with the appearance of extracellular RNA.
For example, RNA released from degenerative or necrotic
cells could contact microglia or astrocytes. Such RNAs
may be recognized by TLR3 or RIG-1, promoting inflam-
mation.10 This extracellular RNA could conceivably stim-
ulate TLR3 signalling, inducing an immune response in
the brain. A report suggested that increased tau protein
phosphorylation at the PHF-1 site (Ser396/404), and JNK
and p38 MAPK activation were observed in poly(I:C)-
treated cells.35
In summary, we demonstrated that TLR3 is abundantly
expressed in cultured brain astrocytes, and its activation
by dsRNA results in MAPK-dependent IL-6 secretion.
Therefore, TLR3 in astrocytes could sense immune
responses during viral infection or some immunological
brain diseases, and play an important role in modulating
immune responses in the brain.
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